With Rigel Pharmaceuticals Inc.’s R333 kaput in Phase II trials for skin lesions in discoid lupus erythematosus patients, attention has turned from the topical JAK/SYK inhibitor to fostamatinib, an oral SYK inhibitor bound for Phase III trials in the first half of next year in immune thrombocytopenic purpura (ITP).